Stephen Brunton, MD, Director of Faculty Development, Cabarrus Family Medicine, Charlotte, North Carolina, reviews the evidence on recent advances in smoking cessation and the novel agent varenicline, an alpha 4 beta 2 Nicotinic Acetylcholine Receptor Partial Agonist.

References and Resources
Gonzales D, Rennard SI, Nides M, et al, for the Varenicline Phase 3 Study Group. Varenicline, an ?4?2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47-55.
Click Here to read the article.

Covey LS, Glassman AH, Jiang H, A randomized trial of bupropion and/or nicotine gum as maintenance treatment for preventing smoking relapse. Addiction. 2007 Aug;102(8):1292-302.
Click Here to read abstract.

Dr. Brunton has disclosed the following:
Consulting Fees: Pfizer, Novo Nordisk, Amylin, Takeda, Novartis

Sponsored by The Doctor’s Channel